At a glance
ClinicalIndex Comparison Record- ✓Age 18-55 years
- ✓Able to read, write English, and provide voluntary written informed consent
- ✓Not currently seeking treatment or using treatment medications
- ✓Tobacco smokers: FTND score ≥3 and ≥7 cigarettes/day for ≥1 year
- ✕Current significant medical condition (neurological, cardiovascular, endocrine, renal, liver, thyroid)
- ✕History of or current neurological or significant psychiatric disorder such as schizophrenia or bipolar disorder
- ✕History of significant head trauma
- ✕Regular or current significant use of prescription, herbal, or illegal psychotropic medications in past 6 months (antidepressants, antipsychotics, anxiolytics, ecstasy)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Imaging the Neurochemistry of Drug Addiction With PET
In Brief
A Early Phase 1 clinical trial evaluating cannabis for Smoking and Cannabis. Completed, enrolled 25 participants across 3 sites.
Detailed Summary
The investigators' project has two overarching goals. 1) The investigators will use newly developed positron emission tomography (PET) technology to investigate the dopaminergic neurochemistry of drugs of abuse including marijuana, traditional cigarettes, and cocaine, and 2) The investigators will extend PET technology to an additional neurotransmitter system - namely, the opioid-ergic system, using the same drugs of abuse.
Study Details
Timeline
Interventions
All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.